Cargando…

Future perspectives on swine viral vaccines: where are we headed?

Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacter...

Descripción completa

Detalles Bibliográficos
Autores principales: Opriessnig, Tanja, Mattei, Ashley A., Karuppannan, Anbu K., Halbur, Patrick G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/
https://www.ncbi.nlm.nih.gov/pubmed/33397477
http://dx.doi.org/10.1186/s40813-020-00179-7
_version_ 1783631534094286848
author Opriessnig, Tanja
Mattei, Ashley A.
Karuppannan, Anbu K.
Halbur, Patrick G.
author_facet Opriessnig, Tanja
Mattei, Ashley A.
Karuppannan, Anbu K.
Halbur, Patrick G.
author_sort Opriessnig, Tanja
collection PubMed
description Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses.
format Online
Article
Text
id pubmed-7780603
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77806032021-01-05 Future perspectives on swine viral vaccines: where are we headed? Opriessnig, Tanja Mattei, Ashley A. Karuppannan, Anbu K. Halbur, Patrick G. Porcine Health Manag Review Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools, including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig viruses. BioMed Central 2021-01-04 /pmc/articles/PMC7780603/ /pubmed/33397477 http://dx.doi.org/10.1186/s40813-020-00179-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Opriessnig, Tanja
Mattei, Ashley A.
Karuppannan, Anbu K.
Halbur, Patrick G.
Future perspectives on swine viral vaccines: where are we headed?
title Future perspectives on swine viral vaccines: where are we headed?
title_full Future perspectives on swine viral vaccines: where are we headed?
title_fullStr Future perspectives on swine viral vaccines: where are we headed?
title_full_unstemmed Future perspectives on swine viral vaccines: where are we headed?
title_short Future perspectives on swine viral vaccines: where are we headed?
title_sort future perspectives on swine viral vaccines: where are we headed?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780603/
https://www.ncbi.nlm.nih.gov/pubmed/33397477
http://dx.doi.org/10.1186/s40813-020-00179-7
work_keys_str_mv AT opriessnigtanja futureperspectivesonswineviralvaccineswhereareweheaded
AT matteiashleya futureperspectivesonswineviralvaccineswhereareweheaded
AT karuppannananbuk futureperspectivesonswineviralvaccineswhereareweheaded
AT halburpatrickg futureperspectivesonswineviralvaccineswhereareweheaded